103596-11-8Relevant articles and documents
Improving triplet excited-state absorption and lifetime of cationic iridium(III) complexes by extending π-conjugation of the 2-(2-quinolinyl)quinoxaline ligand
Kilina, Svetlana,Li, Hui,Liu, Shan,Lystrom, Levi,Sun, Wenfang
, (2020/06/18)
The synthesis and photophysical properties (UV?vis absorption, emission, and transient absorption) of four cationic Ir(III) complexes (C^N)2Ir(R-quqo)+ (HC^N = 1-phenylisoquinoline (piq) and 1,2-diphenylpyreno[4,5-d]imidazole (dppi), quqo = 2-(2-quinolinyl)quinoxaline, R = H or fluorenyl) are reported. The UV–vis absorption and emission were simulated by time-dependent density functional theory (TDDFT). Influences of extending π-conjugation of the C^N ligand and the diimine ligand on the singlet and triplet excited-state absorption and lifetimes of these complexes were explored. All complexes exhibited intense ligand-localized 1π,π transitions, broad and structureless metal-to-ligand charge transfer (1MLCT) / ligand-to-ligand charge transfer (1LLCT) transitions, and very weak spin-forbidden 3MLCT/3LLCT/3π,π transitions in their UV–vis absorption spectra. The two complexes that bear fluorenyl-substituted quqo ligands (Ir-3 and Ir-4) also possessed a broad intraligand charge transfer (1ILCT) / 1π,π band at 430–550 nm. The predominant 3ILCT/3π,π characters of the triplet excited states of Ir-3 and Ir-4 improved their phosphorescent emission quantum yields and prolonged their triplet lifetimes compared to the weaker and short-lived emission of Ir-1 and Ir-2. In contrast to the very weak nanosecond transient absorption (TA) of Ir-1 and Ir-2, Ir-3 and Ir-4 possessed much stronger TA signals at 520?800 nm upon nanosecond laser excitation. These complexes exhibited moderate to strong reverse saturable absorption (RSA) at 532 nm for ns laser pulses, with the RSA trend following Ir-1 > Ir-2 ≈ Ir-3 > Ir-4. Considering the long triplet excited-state lifetimes and broadband TA, complexes Ir-3 and Ir-4 could be potential broadband RSA materials.
TRICYCLIC PI3K INHIBITOR COMPOUNDS AND METHODS OF USE
-
, (2018/03/25)
Described herein are tricyclic compounds with phosphoinositide-3 kinase (PI3K) modulation activity or function having the Formula I structure: or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the Formula I compounds, as well as methods of using such PI3K modulators, alone and in combination with other therapeutic agents, for treating diseases or conditions that are mediated or dependent upon PI3K dysregulation.
